Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Text availability
Article attribute
Article type
Publication date

Search Results

258 results
Filters applied: . Clear all Results are displayed in a computed author sort order. Results by year timeline is unavailable
Page 1
Gene signature in melanoma associated with clinical activity: a potential clue to unlock cancer immunotherapy.
Gajewski TF, Louahed J, Brichard VG. Gajewski TF, et al. Cancer J. 2010 Jul-Aug;16(4):399-403. doi: 10.1097/PPO.0b013e3181eacbd8. Cancer J. 2010. PMID: 20693853 Review.
Antigen-specific regression of established tumors induced by active immunization with irradiated IL-12- but not B7-1-transfected tumor cells.
Fallarino F, Ashikari A, Boon T, Gajewski TF. Fallarino F, et al. Among authors: gajewski tf. Int Immunol. 1997 Sep;9(9):1259-69. doi: 10.1093/intimm/9.9.1259. Int Immunol. 1997. PMID: 9310829
Rational development of tumour antigen-specific immunization in melanoma.
Gajewski TF, Fallarino F. Gajewski TF, et al. Ther Immunol. 1995 Aug;2(4):211-25. Ther Immunol. 1995. PMID: 9358613 Review.
Improved efficacy of dendritic cell vaccines and successful immunization with tumor antigen peptide-pulsed peripheral blood mononuclear cells by coadministration of recombinant murine interleukin-12.
Fallarino F, Uyttenhove C, Boon T, Gajewski TF. Fallarino F, et al. Among authors: gajewski tf. Int J Cancer. 1999 Jan 18;80(2):324-33. doi: 10.1002/(sici)1097-0215(19990118)80:2<324::aid-ijc25>;2-d. Int J Cancer. 1999. PMID: 9935218
Monitoring specific T-cell responses to melanoma vaccines: ELISPOT, tetramers, and beyond.
Gajewski TF. Gajewski TF. Clin Diagn Lab Immunol. 2000 Mar;7(2):141-4. doi: 10.1128/cdli.7.2.141-144.2000. Clin Diagn Lab Immunol. 2000. PMID: 10702484 Free PMC article. No abstract available.
Immunization of HLA-A2+ melanoma patients with MAGE-3 or MelanA peptide-pulsed autologous peripheral blood mononuclear cells plus recombinant human interleukin 12.
Gajewski TF, Fallarino F, Ashikari A, Sherman M. Gajewski TF, et al. Clin Cancer Res. 2001 Mar;7(3 Suppl):895s-901s. Clin Cancer Res. 2001. PMID: 11300489 Clinical Trial.
Epitope spreading upon P815 tumor rejection triggered by vaccination with the single class I MHC-restricted peptide P1A.
Markiewicz MA, Fallarino F, Ashikari A, Gajewski TF. Markiewicz MA, et al. Among authors: gajewski tf. Int Immunol. 2001 May;13(5):625-32. doi: 10.1093/intimm/13.5.625. Int Immunol. 2001. PMID: 11312250
Integrating IL-12 into therapeutic cancer vaccines.
Gajewski TF. Gajewski TF. Cancer Chemother Biol Response Modif. 2002;20:343-9. Cancer Chemother Biol Response Modif. 2002. PMID: 12703213 Review. No abstract available.
Immunization with Melan-A peptide-pulsed peripheral blood mononuclear cells plus recombinant human interleukin-12 induces clinical activity and T-cell responses in advanced melanoma.
Peterson AC, Harlin H, Gajewski TF. Peterson AC, et al. Among authors: gajewski tf. J Clin Oncol. 2003 Jun 15;21(12):2342-8. doi: 10.1200/JCO.2003.12.144. J Clin Oncol. 2003. PMID: 12805336 Clinical Trial.
Clinical responses following nonmyeloablative allogeneic stem cell transplantation for renal cell carcinoma are associated with expansion of CD8+ IFN-gamma-producing T cells.
Harlin H, Artz AS, Mahowald M, Rini BI, Zimmerman T, Vogelzang NJ, Gajewski TF. Harlin H, et al. Among authors: gajewski tf. Bone Marrow Transplant. 2004 Mar;33(5):491-7. doi: 10.1038/sj.bmt.1704385. Bone Marrow Transplant. 2004. PMID: 14716341 Clinical Trial.
258 results
You have reached the last page of results. A maximum of 10,000 results are available.
Jump to page